3SBio's shares surged 32% to 19.18 Hong Kong dollars, equivalent to US$2.45, on Tuesday after the Chinese company said it would receive an upfront payment of US$1.25 billion and potential milestone ...

Chinese biotech company 3SBio's shares surged early Tuesday after its around US$6 billion licensing deal with Pfizer to develop, manufacture and commercialize a promising cancer drug. Shares were up ...

Contrarian investing advice from biotech and pharmaceutical stock expert Hartaj Singh, Founding Partner of Tecumseh Partners ...

The FDA is changing how drugs get approved—and that could unleash a biotech revolution. Dylan Jovine from Behind the Markets shares 4 biotech companies on the verge of explosive breakthroughs, ...

The demand for the widely used cancer drug Taxol is increasing, but it's difficult and expensive to produce because it hasn't ...

BioNTech's BNT324 aims to outpace rivals in cancer treatment with its unique bispecific antibody design. Read more here.

Two excellent candidates are Vertex Pharmaceuticals ( VRTX -1.05%) and Axsome Therapeutics ( AXSM -1.06%). Here's what makes ...

If Recursion Pharmaceuticals can achieve its goal of cutting the time and money it takes to develop drugs by meaningful ...

“By identifying opportunities to bring in stable revenue, we believe the Company can reduce its need for capital that could be dilutive to the stock price,” Latkin said. The real estate ...

TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, received notice today from the Nasdaq Stock Market LLC ...

A California-based biotech company is absolutely stealing the spotlight after it was announced that Novartis AG is set to acquire it. The press release mentions that Novartis is to acquire the ...